2-(3-溴苯基)-恶唑 | 885274-35-1

• 物质功能分类: 生物 - 细胞培养 - 添加剂
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2-(3-溴苯基)-恶唑
• 中文别名: 2-(3-溴苯基)-噁唑
• 英文名称: 2-(3-bromophenyl)oxazole
• 英文别名: 2-(3-Bromophenyl)-1,3-oxazole
• CAS: 885274-35-1
• 化学式: C₉H₆BrNO
• 分子量: 224.057
• InChiKey: YLPWYXWXKUAHPU-UHFFFAOYSA-N

物化性质

• 沸点：
  309.8±44.0 °C(Predicted)
• 密度：
  1.524±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2934999090

制备方法与用途

2-(3-溴苯基)-恶唑是一种杂环有机化合物，可用作医药中间体。

反应信息

• 作为反应物：
  描述：

  2-(3-溴苯基)-恶唑 在 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 caesium carbonate 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 6.0h， 生成 5-methoxy-2-morpholino-6-(3-(oxazol-2-yl)phenyl)-N-(pyridin-4-yl)pyrimidin-4-amine
  参考文献：
  名称：

  [EN] PYRIMIDINES AND METHODS OF THEIR USE
  [FR] PYRIMIDINES ET LEURS PROCÉDÉS D'UTILISATION

  摘要：

  Disclosed are compounds comprising pyrimidinyl core and pharmaceutical compositions useful in the treatment of neurological disorders. The compounds described herein, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological diseases, including FTLD-TDP, chronic traumatic encephalopathy, ALS, Alzheimer's disease, LATE, or frontotemporal lobar degeneration.

  公开号：

  WO2023107603A1
• 作为产物：
  描述：

  恶唑 、 1-溴-3-碘苯 在 copper(l) iodide 、 palladium diacetate 作用下， 以 N,N-二甲基乙酰胺 为溶剂， 以76.7 %的产率得到2-(3-溴苯基)-恶唑
  参考文献：
  名称：

  [EN] PYRIMIDINES AND METHODS OF THEIR USE
  [FR] PYRIMIDINES ET LEURS PROCÉDÉS D'UTILISATION

  摘要：

  Disclosed are compounds comprising pyrimidinyl core and pharmaceutical compositions useful in the treatment of neurological disorders. The compounds described herein, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological diseases, including FTLD-TDP, chronic traumatic encephalopathy, ALS, Alzheimer's disease, LATE, or frontotemporal lobar degeneration.

  公开号：

  WO2023107603A1

文献信息

• 2-SPIRO-SUBSTITUTED IMINOTHIAZINES AND THEIR MONO-AND DIOXIDES AS BACE INHIBITORS, COMPOSITIONS AND THEIR USE
  申请人：Wu Wen-Lian

  公开号：US20140200213A1

  公开（公告）日：2014-07-17

  In its many embodiments, the present invention provides certain iminothiazine dioxide compounds, including compounds Formula (I): and tautomers and stereoisomers thereof, and pharmaceutically acceptable salts of said compounds, said tautomeros and said stereoisomers, wherein each of the variables shown in the formula are as defined herein. The novel compounds of the invention are useful as BACE inhibitors and/or for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including Alzheimer's disease, are also disclosed.

  在其多种实施方式中，本发明提供了某些亚胺噻唑二氧化物化合物，包括化合物式（I）的化合物及其互变异构体和立体异构体以及所述化合物、所述互变异构体和所述立体异构体的药学上可接受的盐，其中公式中所示的每个变量如本文所定义。本发明的新型化合物可用作BACE抑制剂和/或用于治疗和预防与之相关的各种病理。还披露了包含一种或多种这样的化合物（单独和与一种或多种其他活性剂的组合）的制药组合物以及其制备和使用方法，包括治疗阿尔茨海默病。
• ALKYNYL ALCOHOLS AND METHODS OF USE
  申请人：Genentech, Inc.

  公开号：US20160200739A1

  公开（公告）日：2016-07-14

  The invention relates to compounds of Formula (0): wherein Q, A 1 -A 8 , R 4 and R 5 and each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.

  本发明涉及公式（0）的化合物：其中Q，A1-A8，R4和R5均具有如下所述的含义。公式（0）的化合物和其制备的药物组合物在治疗观察到NF-kB信号不必要或过度激活的疾病和疾病中非常有用。
• TRICYCLIC SUBSTITUTED THIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP2908824B1

  公开（公告）日：2018-05-02
• NOVEL 3-INDOL SUBSTITUTED DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE
  申请人：Iteos Therapeutics

  公开号：EP3119763A1

  公开（公告）日：2017-01-25
• FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST
  申请人：RaQualia Pharma Inc.

  公开号：EP3774739B1

  公开（公告）日：2022-05-11